報價延遲最少15分鐘:2024/12/24 12:25 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.42 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.43/-2.40
|
|
企業價值
510.46M
|
| 資產負債 |
|
每股賬面淨值
3.25
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 12:25 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Theyare evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD. |